Hemophilia A is a serious blood clotting disorder caused by a lack of factor VIII, a
specialized protein needed for normal blood clotting to occur. Individuals with this disease
may experience spontaneous bleeding, pain and swelling in their joints due to excess
bleeding, and bruising. A common treatment for severe hemophilia A is to intravenously
replace the deficient blood clotting factor; however, some individuals may develop antibodies
to this replacement factor. This study will evaluate the effectiveness of rituximab at
reducing the antibodies that develop in response to the replacement factor in individuals
with severe hemophilia A.
Phase:
Phase 2
Details
Lead Sponsor:
HealthCore-NERI New England Research Institutes
Collaborators:
Genentech, Inc. National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Blood Coagulation Factor Inhibitors Factor VIII Rituximab